Targeting both RNA and the proteins that interact with it has become one of the hottest new areas in drug discovery. Biotechs such as Storm Therapeutics, 28-7, Gotham Therapeutics and Accent Therapeutics amongst many others, are all developing small molecule inhibitors of misregulated epigenetic processes.
On Wednesday, June 30th at 1pm EDT ZoBio will organize together with Cambridge Healthtech Institute the webinar: “Epitranscriptomics and Disease: The Role of RNA Modification in the Life Cycle of the Cell”. During the webinar two of the top experts in the field: Samie R. Jaffrey, the Greenberg-Starr Professor in the Department of Pharmacology at the Weill Cornell Medical College and Sebastian Leidel, Professor in the Department of Chemistry, Biochemistry and Pharmaceutical Sciences (DCBP) University of Bern will highlight an exciting developments on RNA modifications and epitranscriptomics.
Both key opinion leaders will share their insights into the mechanisms of epitranscriptomics and its relationship to disease, in particular oncology. They will describe their latest findings on important targets and the biological outcome of inhibiting them. In addition, ZoBio will share a case study on development of small molecule inhibitors of an epitranscriptomic target. In all, the webinar will bring you insights into the field, the propsects for drug discovery and what it takes to be successful if you chose to pursue it.
Register via the Online Registration form in order to receive the access credentials to the Webinar.
We hope you are as excited about this webinar as we are!